10-Q/A: Solsence Inc. Restates Financials Amidst Internal Control Weaknesses

Solsence, Inc. has filed an amendment to its Q3 2025 10-Q report to restate financial statements due to errors in inventory accounting, revealing material weaknesses in internal controls.

Summary

• Solsence, Inc. (formerly Nanophase Technologies Corporation) has filed an amendment (Form 10-Q/A) to its quarterly report for the period ended September 30, 2025, to restate its previously issued financial statements.
• The restatement is due to errors identified in historical accounting for labor and overhead included in inventories, leading to overstatements in inventory and misstatements in cost of revenue.
• These errors impacted gross profit, operating income, net income, and equity.
• Management identified material weaknesses in internal controls over financial reporting, specifically in inventory costing and oversight/review of financial reporting and restatement activities.
• As a result, the company's disclosure controls and procedures were not effective as of September 30, 2025.
• Total revenue for the nine months ended September 30, 2025, increased to $49,581,000 from $39,780,000 in the prior year period.
• However, total revenue for the three months ended September 30, 2025, decreased to $14,597,000 from $16,866,000 in the prior year period.
• The company received a significant payment of $1,729,000 plus interest under the Employee Retention Credit (ERC) program in June 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to the restatement of financial statements and identification of material weaknesses in internal controls, despite some revenue growth in the nine-month period.

Positives

• Total revenue for the nine months ended September 30, 2025, increased by 24.6% to $49,581,000 compared to $39,780,000 in the same period of 2024.
• Product revenue for the nine months ended September 30, 2025, increased to $49,369,000 from $39,479,000 in the prior year period, driven by higher sales in consumer products.
• The company received a $1,729,000 payment plus $272,000 in interest from the U.S. Department of the Treasury under the Employee Retention Credit (ERC) program in June 2025, which was recognized as income.
• The company's common stock was uplisted to Nasdaq under the symbol SLSN on April 8, 2025.

Negatives

• The company is restating its previously issued financial statements for the period ended September 30, 2025, due to errors in inventory accounting.
• Material weaknesses were identified in internal controls over financial reporting related to inventory costing and oversight/review of financial reporting and restatement activities.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025.
• Inventories were overstated by $3.742 million at September 30, 2025, and $4.651 million at December 31, 2024, due to the restatement.
• Accumulated deficit increased by $3.742 million at September 30, 2025, and $4.651 million at December 31, 2024, as a result of the restatement.
• Total revenue for the three months ended September 30, 2025, decreased to $14,597,000 from $16,866,000 in the prior year period.
• Net loss for the three months ended September 30, 2025, was $1,016,000, compared to a net income of $2,720,000 for the same period in 2024.
• Selling, general and administrative expenses increased significantly by 58.7% for the three months and 53.8% for the nine months ended September 30, 2025, compared to the prior year periods.

Risks

• The company's dependence on a limited number of key customers could lead to significant revenue loss if a customer cancels a purchase order or supply agreement.
• Potential inability to obtain working capital when needed on acceptable terms or at all.
• Uncertain demand for and acceptance of Solsence products and advanced materials.
• The terms of supply agreements with BASF could trigger a requirement to sell production equipment if performance requirements are not met, potentially resulting in the loss of a significant revenue source.
• Potential inability to obtain materials at costs that can be passed through to customers, including rare earth elements and high purity zinc.
• The impact of any potential new governmental regulations, especially those concerning the processing, handling, storage, or sale of nanomaterials, could be difficult to respond to or costly to comply with.
• Business interruptions due to unexpected events or public health crises.
• The resolution of litigation or other legal proceedings in which the company may become involved.

Future Outlook

The company's future capital requirements will depend on customer acceptance of its products, R&D progress, expansion of manufacturing capabilities, and market development. Capital spending for 2025 is projected between $0.1 million and $1 million, funded by operations, existing credit lines, and potential new debt financing. Management expects margins to increase as product revenue volume grows and fixed manufacturing costs are more efficiently absorbed. The company is focused on reducing controllable variable product manufacturing costs.

Management Comments

• Management has re-evaluated the effectiveness of internal controls over financial reporting as of September 30, 2025, and identified material weaknesses.
• Management concluded that the company's internal controls and disclosure controls and procedures were not effective as of September 30, 2025.
• The company intends to implement remediation measures for inventory costing and financial reporting oversight.
• Management believes that consumer products should be the major focus of the growth strategy due to expanding demand and favorable market conditions.
• Management believes inflation has had an incremental impact on costs to date but warns of potential material effects in 2025 if cost increases cannot be passed on.

Industry Context

StockSavvy.ai notes that Solsence operates in the beauty and life sciences markets, with a strategic focus on skin health. The company's reliance on consumer products and ingredients for skincare and sunscreens aligns with broader market trends favoring scientifically-backed, clean beauty products. However, the identified material weaknesses in financial reporting and inventory accounting are significant concerns that could impact investor confidence in a sector that often demands high levels of transparency and accuracy.

Comparison to Industry Standards

• The restatement of financial statements due to inventory costing errors indicates a deviation from the expected standard of accurate financial reporting for publicly traded companies.
• The identification of material weaknesses in internal controls suggests a failure to meet the robust internal control frameworks (e.g., COSO) typically expected by investors and auditors.
• While revenue growth in the nine-month period is positive, the overall financial performance and the need for restatement place Solsence in a less favorable position compared to industry peers with stable financial reporting and strong internal controls.
• Competitors in the specialty materials and consumer product ingredient sectors generally maintain higher standards of financial reporting accuracy and internal control effectiveness.

Corporate Governance

Related Party Transactions

• The company has outstanding balances and credit facilities with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, a majority shareholder.
• Related party interest expense was $338,000 for the three months and $795,000 for the nine months ended September 30, 2025.
• Outstanding balances with Beachcorp, LLC were $14,816,000 as of September 30, 2025.
• Outstanding balances with Strandler, LLC were $1,000,000 as of September 30, 2025.

Stakeholder Impact

• Shareholders: The restatement of financial statements and material weaknesses in internal controls may negatively impact investor confidence and the stock price.
• Creditors: The company's financial reporting issues and potential liquidity concerns could affect its ability to service debt.
• Suppliers: Increased scrutiny on financial reporting may lead to more stringent credit terms or payment requirements.
• Employees: Uncertainty surrounding financial stability and internal control issues could impact employee morale.

Next Steps

• Implement remediation measures for inventory costing and financial reporting oversight.
• Continue to focus on expanding sales of consumer products and APIs.
• Monitor and manage the impact of inflation on costs and pricing.
• Potentially seek new debt financing to fund capital expenditures.
• The company will continue to determine whether to provide additional scaled disclosures if it remains a smaller reporting company.

Key Dates

Recommendation

The restatement of financial statements due to significant inventory accounting errors and the identification of material weaknesses in internal controls are critical red flags. While there was revenue growth in the nine-month period, the net loss in the most recent quarter and the ongoing issues with financial reporting reliability suggest a high level of risk. Investors should consider selling or avoiding the stock until these control deficiencies are fully remediated and the company demonstrates consistent, reliable financial reporting.

Keywords

inventory accounting, financial restatement, internal controls, material weakness, SEC filing, consumer products, personal care ingredients, advanced materials